April 2013

HESI in Asia

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Technical Committees Launch Two New Work Groups

HESI PATC / IFBiC Biotech Workshop.

Workshop on "Rechanneling the Current Concerns of Genetic Toxicology of Pharmaceutical and Environmental Chemicals" will be held at the US FDA Workshop Recommendations and a New Working Group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Technical Committees Launch Two New Work Groups

HESI PATC / IFBiC Biotech Workshop.

Workshop on "Rechanneling the Current Concerns of Genetic Toxicology of Pharmaceutical and Environmental Chemicals" will be held at the US FDA Workshop Recommendations and a New Working Group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.

New HESI Publications

FROM THE EXECUTIVE DIRECTOR

HESI Annual Meeting.

Workshop on "Moving Forward in Human Cancer Risk Assessment in the Genomics Era" was held on 26–27 May 2013, the HESI Applications of Genomic Technologies Committee (AGTC) held its annual meeting in Tokyo, Japan. The workshop recommendations and a new working group on "New Frontiers in Cancer Risk Assessment" will be held on the U.S. Food and Drug Administration (FDA) White Oak Conference Center, Silver Spring, Maryland. This workshop will introduce a new paradigm to assess new cancer risks that use multiomics data. The workshop will strengthen and expand the CDER's translational knowledge database in cancer risk assessment. For more information, please link to Dr. Connie Chen (cmembry@hesiglobal.org) or HESI Scientific Advisor in Japan.